# Aurigene Pharmaceutical Services plans $40M biotherapeutics facility in Hyderabad

Aurigene Pharmaceutical Services, a subsidiary of Dr. Reddy's Laboratories, announced a $40 million investment to build a production facility for therapeutic proteins, antibodies and viral vectors at Genome Valley in Hyderabad, India. The facility is expected to be fully operational by the first half of 2024.

- Type: Expansion
- Announced: 2023-05-22
- Where: Genome Valley, Hyderabad, India, India
- Value: $40.0M
- Starts operating: Q3 2024
- Status: announced
- Products: therapeutic proteins, antibodies, viral vectors
- Sectors: [Medical Devices](https://endata.com/sectors/medical-devices.md)

## Companies

- [Aurigene Pharmaceutical Services](https://endata.com/companies/70479.md)
- [Dr. Reddy's Laboratories](https://endata.com/companies/70480.md) (investor)

## Sources

- [fiercepharma.com](https://www.fiercepharma.com/manufacturing/dr-reddys-subsidiary-aurigene-plans-40m-expansion-india), 2023-05-25: "With this expansion in biotherapeutics CDMO, we will be positioned to provide integrated services from clinical research to commercial manufacturing for small and large molecules."

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.